Thrombosis in Myeloid Malignancies, from CHIP to AML.
Acute Myeloid Leukemia
Acute Promyelocytic Leukemia
Clonal Hemopoiesis of indeterminate potential
Myelodysplastic Syndromes
Thrombosis
VEXAS Syndrome
Journal
Cardiovascular & hematological disorders drug targets
ISSN: 2212-4063
Titre abrégé: Cardiovasc Hematol Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269160
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
29
01
2024
revised:
18
04
2024
accepted:
30
04
2024
medline:
16
6
2024
pubmed:
16
6
2024
entrez:
16
6
2024
Statut:
aheadofprint
Résumé
The development of myeloid malignancies is a multi-step process starting from pre-malignant stages. Large-scale studies on clonal hematopoiesis of indeterminate potential (CHIP) identified this condition as a risk factor for developing hematologic malignancies, in particular myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In parallel, CHIP was found to confer an enhanced thrombotic risk, in particular for cardiovascular diseases. In a similar fashion, in recent years, alongside their life-threatening features, increasing attention has been drawn toward thrombotic complications in myeloid malignancies. The purpose of this review is to gather growing body of evidence on incidence, pathogenesis and clinical impact of thrombosis in myeloid malignancies at every step of malignant progression, from CHIP to AML.
Identifiants
pubmed: 38879768
pii: CHDDT-EPUB-140967
doi: 10.2174/011871529X307253240530060107
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.